Multiple immunomodulatory agents targeting different immune checkpoints such as programmed cell death-1 (PD-1), programmed cell death ligand-1(PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) are under investigation in various types of cancer. This evidence concerns the gene PDCD1 and cancer.